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Background
Exposure to certain strains of human papilloma virus
(HPV) promotes dysplasia in cells of the anal canal
epithelium, leading to AIN, which is in turn a precursor
to squamous cell carcinoma of the anus (SCCA).
Patients with HIV infection who have anoreceptive
intercourse are at heightened risk for acquiring HPV,
AIN, and SCCA. The use of topical 5-FU to prevent the
progression of lower genital tract neoplasia to invasive
cervical carcinoma has been studied in both HIV+ and
HIV- women. Although intravenous 5-FU is also com-
monly used for treatment of invasive SCCA, there has
been little experience with the use of topical 5-FU as
therapy for AIN.
Materials and methods
We retrospectively reviewed medical records from our
anal dysplasia clinic. Our study population comprised
11 HIV+ men with biopsy-proven AIN who were trea-
ted with topical 5-FU. All patients were initially
instructed to apply a pea-sized amount of topical 5-FU
to the anus each night, to wash their hands afterwards,
and to wipe away excess 5-FU in the morning. Patients
reduced the frequency of application if they experienced
undue local irritation.
Results
Patient data are summarized in Table 1. 6 of 11 (55%)
patients showed improvement in clinical appearance.
Anoscopy images for one of these patients before and
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Table 1
Age range in years (median) 32-67 (45)
On HAART (%) 9 (82%)
CD4+ cell count/µL range (median) 35-730 (416)
HIV viral copies/mL range (median) <75-172,966 (<75)
Treatment duration range (median) 7 wks-6 mo (20 wks)
Clinically improved (%) 6 (55%)
Perianal irritation (%) 8 (73%)
Anal fissure (%) 1 (9%)
Perianal HSV (%) 1 (9%)
Decreased dosing frequency (%) 6 (55%)
Discontinued (%) 1 (9%)
Figure 1 Before Topical 5-FU.
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© 2010 Snyder et al; licensee BioMed Central Ltd.after treatment are shown in Figures 1 and 2, respec-
tively; note the diffusely verrucous appearance in
Figure 1 (arrows).
While all patients had biopsies of the areas with the
most clinically severe dysplasia pre-treatment, only
6 had biopsies post-treatment, and of those only
2 showed improvement in pathologic grade on biopsy.
6 (55%) patients decreased frequency of 5-FU applica-
tion due to mild to moderate perianal irritation.
Conclusions
Patients tolerated topical 5-FU without significant side
effects. Our results are preliminary, but suggest a role
for topical 5-FU in reducing disease burden in anal dys-
plasia. While this therapy may not eliminate areas with
the worst dysplasia, reducing disease burden may facili-
tate the use of destructive modalities to treat residual
areas of high-grade dysplasia.
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Figure 2 After Topical 5-FU.
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